Geneva Health partners with Ochsner in remote cardiac monitoring

EKG rhythm
Recently, Geneva reported triple-digit revenue growth in 2018, alongside a tripling of its client base and its workforce. (Pixabay / PublicDomainPictures)

Ochsner Health System has tapped Geneva Health Solutions to manage data collection and remote monitoring of its patients with implanted cardiac devices across the southern U.S.

Geneva will gather data from implanted pacemakers, defibrillators, loop recorders and other devices and integrate them into the health system’s established Epic electronic medical record. It will be the first time Geneva’s cloud-based platform will be used in the region, spanning Ochsner’s 30 hospitals and more than 80 health centers across Louisiana, Arkansas, Mississippi, Alabama and Georgia.

It will also allow providers to schedule device follow-ups or respond to issues—as well as manage alerts for events such as atrial fibrillation or other indicators of heart failure—as it aggregates data from home use, in addition to office, ER or hospital visits.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Recently, Geneva reported triple-digit revenue growth in 2018, alongside a tripling of its client base and its workforce, and said it expects an explosion of cardiac device data over the next year.

Describing a “data deluge” from implanted devices, Geneva CEO Yuri Sudhakar pointed to how cardiac practice staff can be overextended and overwhelmed in trying to deal with the amount of incoming information.

Currently, Geneva’s remote monitoring includes more than 30,000 patients at over 45 cardiology sites, the company said.

Suggested Articles

Acceleron’s sotatercept outdid placebo at reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.

A new company focusing on sperm rather than egg biology debuted with goals of increasing fertility rates and reducing pregnancy complications.